+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Esophageal Cancer

  • ID: 4533508
  • Report
  • 42 pages
  • Datamonitor Healthcare
1 of 2
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways:
  • The author estimates that in 2017, there were 488,800 incident cases of esophageal cancer worldwide, and expects that number to increase to 534,700 incident cases by 2026.
  • Incidence is higher in males compared to females, and is highest in the Asia region. Photofrin, a two-step therapy that involves the injection of the photoactive drug followed by drug activation using laser therapy, is the only FDA-approved drug for esophageal cancer.
  • The majority of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II. Therapies in development for esophageal cancer focus on a wide variety of targets. The majority of pipeline drugs in mid-to-late stage development are administered intravenously, with three drugs being tested in oral formulations.
  • The only high-impact upcoming event in the esophageal cancer space is topline Phase III trial results for Opdivo. The overall likelihood of approval of a Phase I solid tumor asset is 5.7%, and the average probability a drug advances from Phase III is 39.4%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
  • There have been 10 licensing and asset acquisition deals involving esophageal cancer drugs during 2014–19. The $1,456m drug development collaboration agreement signed in 2015 between Eli Lilly and Innovent Biologics to support the development and potential commercialization of at least three cancer treatments was the largest deal.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
  • The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the esophageal cancer space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for esophageal cancer, with 89 trials.
  • Roche and Sanofi lead industry sponsors with the highest number of clinical trials for esophageal cancer.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Surgery
Radiation therapy
Endoscopic therapy
Chemotherapy
Targeted therapy
Immunotherapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
Keytruda for Esophageal Cancer (January 14, 2019)
Opdivo for Esophageal Cancer (January 9, 2019)
Keytruda for Esophageal Cancer (November 14, 2018)
Keytruda for Esophageal Cancer (June 3, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
Merck’s Keytruda Shows Utility In Subset Of Esophageal Cancer

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase

BIBLIOGRAPHY
Prescription information

APPENDIX

LIST OF FIGURES
Figure 1: Trends in incident cases of esophageal cancer, 2017–26
Figure 2: Incident cases of esophageal cancer, by gender, 2017
Figure 3: Overview of pipeline drugs for esophageal cancer in the US
Figure 4: Pipeline drugs for esophageal cancer, by company
Figure 5: Pipeline drugs for esophageal cancer, by drug type
Figure 6: Pipeline drugs for esophageal cancer, by classification
Figure 7: Keytruda for Esophageal Cancer (January 14, 2019): Phase III - KEYNOTE-181
Figure 8: Opdivo for Esophageal Cancer (January 9, 2019): Phase III - ATTRACTION-3
Figure 9: Keytruda for Esophageal Cancer (November 14, 2018): Phase III - KEYNOTE-181
Figure 10: Keytruda for Esophageal Cancer (June 3, 2018): Phase II - KEYNOTE-180
Figure 11: Key upcoming events in esophageal cancer
Figure 12: Probability of success in the esophageal cancer pipeline
Figure 13: Licensing and asset acquisition deals in esophageal cancer, 2014–19
Figure 14: Parent patents in esophageal cancer
Figure 15: Clinical trials in esophageal cancer
Figure 16: Top 10 drugs for clinical trials in esophageal cancer
Figure 17: Top 10 companies for clinical trials in esophageal cancer
Figure 18: Trial locations in esophageal cancer
Figure 19: Esophageal cancer trials status
Figure 20: Esophageal cancer trials sponsors, by phase

LIST OF TABLES
Table 1: Incident cases of esophageal cancer, 2017–26
Table 2: Marketed drugs for esophageal cancer
Table 3: Pipeline drugs for esophageal cancer in the US
Table 4: Keytruda for Esophageal Cancer (January 14, 2019)
Table 5: Opdivo for Esophageal Cancer (January 9, 2019)
Table 6: Keytruda for Esophageal Cancer (November 14, 2018)
Table 7: Keytruda for Esophageal Cancer (June 3, 2018)
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/4533508
Adroll
adroll